Ocular Manifestations in Rheumatic Diseases

Macular Edema Clinical Trial

Official title:

Prevalence of Ocular Manifestations in Inflammatory Rheumatic Diseases

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03753893
• Other study ID #: MTJP001
• Status: Completed
• Start date: May 1, 2013
• Est. completion date: November 1, 2021

Study information

• Verified date: April 2022
• Source: Lawson Health Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a search strategy for determining the prevalence of ocular complications in inflammatory rheumatic diseases for the purposes of a meta analysis.

Description:

For the purposes of determining the prevalence of ocular complications in inflammatory rheumatic diseases, the following search terms were used: conjunctivitis, keratoconjunctivitis sicca, xerophthalmia, uveitis, eye hemorrhage, optic neuritis, papilledema, orbital disease, retinal artery/vein occlusion, macular edema, retinitis, chorioretinitis, scleritis, iridocyclitis, choroid hemorrhage, blindness and amaurosis fugax.

These terms were searched in the context of a corresponding inflammatory disease on Medline, Cochrane and Web of Science from their inception (1966, 1991 and 1990 respectively) until the point of study completion.

Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in an inflammatory rheumatic disease. Studies were excluded if they were review articles, case reports where all patients experienced the same ocular comorbidity, if different comorbidities were not grouped independently, and if the study reported on fewer than 20 patients. When the same study cohort was used in more than one analysis, the most recent or largest sample-size study was included. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to assess the quality of cohort, case-control, and cross-sectional studies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5000
• Est. completion date: November 1, 2021
• Est. primary completion date: April 1, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Studies were included if they provided numerical data of the prevalence or incidence of ocular manifestations in inflammatory rheumatic disease

Exclusion Criteria:

• review articles,

• case reports where all patients experienced the same ocular comorbidity

• if different comorbidities were not grouped independently

• if the study reported on fewer than 20 patients

Related Conditions & MeSH terms

• Amaurosis Fugax
• Blindness
• Chorioretinitis
• Choroid Hemorrhage
• Collagen Diseases
• Conjunctivitis
• Dry Eye Syndromes
• Eye Hemorrhage
• Hemorrhage
• Iridocyclitis
• Keratoconjunctivitis
• Keratoconjunctivitis Sicca
• Macular Edema
• Neuritis
• Optic Neuritis
• Orbital Diseases
• Papilledema
• Retinal Artery Occlusion
• Retinal Vein Occlusion
• Retinitis
• Rheumatic Diseases
• Scleritis
• Uveitis
• Xerophthalmia

Intervention

Other:
• No intervention used
no intervention used

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Lawson Health Research Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of ocular manifestations of inflammatory rheumatic diseases	Prevalence of ocular manifestations of inflammatory rheumatic diseases	data is collected once per year up to 2020